BDNF/BDNF-AS Gene Polymorphisms Modulate Treatment Response and Remission in Bipolar Disorder: A Randomized Clinical Trial DOI Open Access

Anton Shkundin,

Heather E. Wheeler, James Sinacore

et al.

Journal of Personalized Medicine, Journal Year: 2025, Volume and Issue: 15(2), P. 62 - 62

Published: Feb. 7, 2025

Background: Bipolar disorder (BD) is a chronic condition associated with treatment resistance, cognitive decline, structural brain changes, and an approximately 13-year reduction in life expectancy compared to the general population. Depression BD substantially impairs quality of life, while neuroinflammation excitotoxicity are thought contribute recurrence mood episodes disease progression. Brain-derived neurotrophic factor (BDNF) plays key role neuronal growth function, its dysregulation being linked various psychiatric disorders. This study extension previously published clinical trial was conducted assess effects three BDNF BDNF-AS gene polymorphisms (rs1519480, rs6265, rs10835210) on outcomes serum levels patients treatment-resistant bipolar depression (TRBDD) over eight-week period. Methods: included 41 participants from randomized trial, all whom had available samples genotype data. The participants, aged 21 65, were diagnosed disorder, assessed using Maudsley Staging Method. Participants randomly assigned receive either escitalopram plus placebo (ESC+PBO) or celecoxib (ESC+CBX) 8-week Statistical analyses mixed ANOVA chi-square tests compare minor allele carrier status SNPs response remission rates. Results: Non-carriers rs6265 A (p = 0.005) carriers rs10835210 0.007) showed significantly higher adjunctive alone. Additionally, rates after both non-carriers across However, notably rs1519480 G allele, as well allele. Conclusions: suggests that genetic variations genes influence disorder.

Language: Английский

BDNF/BDNF-AS Gene Polymorphisms Modulate Treatment Response and Remission in Bipolar Disorder: A Randomized Clinical Trial DOI Open Access

Anton Shkundin,

Heather E. Wheeler, James Sinacore

et al.

Journal of Personalized Medicine, Journal Year: 2025, Volume and Issue: 15(2), P. 62 - 62

Published: Feb. 7, 2025

Background: Bipolar disorder (BD) is a chronic condition associated with treatment resistance, cognitive decline, structural brain changes, and an approximately 13-year reduction in life expectancy compared to the general population. Depression BD substantially impairs quality of life, while neuroinflammation excitotoxicity are thought contribute recurrence mood episodes disease progression. Brain-derived neurotrophic factor (BDNF) plays key role neuronal growth function, its dysregulation being linked various psychiatric disorders. This study extension previously published clinical trial was conducted assess effects three BDNF BDNF-AS gene polymorphisms (rs1519480, rs6265, rs10835210) on outcomes serum levels patients treatment-resistant bipolar depression (TRBDD) over eight-week period. Methods: included 41 participants from randomized trial, all whom had available samples genotype data. The participants, aged 21 65, were diagnosed disorder, assessed using Maudsley Staging Method. Participants randomly assigned receive either escitalopram plus placebo (ESC+PBO) or celecoxib (ESC+CBX) 8-week Statistical analyses mixed ANOVA chi-square tests compare minor allele carrier status SNPs response remission rates. Results: Non-carriers rs6265 A (p = 0.005) carriers rs10835210 0.007) showed significantly higher adjunctive alone. Additionally, rates after both non-carriers across However, notably rs1519480 G allele, as well allele. Conclusions: suggests that genetic variations genes influence disorder.

Language: Английский

Citations

0